

26. 少なくとも1眼の視力が良好な黄斑疾患症例の

視覚関連 quality of life

小畑 亮^{1) 2)}、柳 靖雄¹⁾、上 順子¹⁾、井上裕治¹⁾
高橋秀徳¹⁾、入山 彩¹⁾、玉置泰裕¹⁾、新家 眞¹⁾
(¹⁾ 東京大、²⁾ さいたま赤十字)

研究要旨 The 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) は視覚関連 QOL の定量的かつ包括的評価法であり、過去の黄斑疾患症例に対する検討報告では、視力が良好である方の眼の視力が多くの下位尺度スコアに強く相関している。今回少なくとも1眼の視力は0.7以上と比較的良好である黄斑疾患症例に限って、QOLスコアおよび年齢、性別、または視力との関連について検討した。東京大学附属病院眼科を受診した黄斑疾患症例に対してVFQ-25日本語版による調査を行い、少なくとも1眼の小数視力が0.7以上の症例55例(男性38例、女性17例、年齢27-91歳)に対して、回答数が稀少であった「運転」を除く11項目のVFQ-25下位尺度スコアを算出し、各スコアと性別、年齢、良好眼logMAR視力、および不良眼logMAR視力との関連の有無について相関分析および重回帰分析を用いて検討した。全症例では年齢と、「心の健康」または「役割制限」のスコアに有意な関連を認めたが、性別、良好眼視力、または不良眼視力とは関連を認めなかった。さらに、60歳以下の症例群では、不良眼視力と「心の健康」または「役割制限」のスコアに有意な関連を認めた。少なくとも1眼の視力は0.7以上と比較的良好である黄斑疾患症例においては、年齢と「心の健康」および「役割制限」との関連を認め、また60歳以下の症例においては不良眼視力と「心の健康」および「役割制限」が関連した。

A. 研究目的

The 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) は、質問票を用いたプロフィール型の視覚関連QOL測定尺度であり、25およびオプション14項目の質問により、日常活動の制限、それに伴う精神面及び社会生活への影響といった下位尺度から、視機能に関連したQOLを総合評価することが可能である。日本語翻訳版が作成されており、既に信頼性・妥当性が検証済みであるのが特長であ

る。^{1 2}

黄斑疾患症例に対するVFQ-25測定については、加齢黄斑変性症例に対して、行われた検討報告において、良い方の眼の視力と多くの下位尺度(全体的見え方、近見行動、遠見行動、社会生活、心の健康、役割制限、自立)が強く相関していること^{3 4}、また、良好眼視力の変化が、VFQ-25の前身であり51の質問項目からなる、VFQ-51のスコア変化と相関すること⁵が報告されている。すなわち、視力良好眼の状態がQOLスコアに関

連しすることはよく知られている。しかし黄斑疾患の臨床経過においては、両眼が同時に視力低下することは稀であり、まず片眼(いわゆる first eye)が罹患し、その後僚眼(second eye)に及ぶことがほとんどである。過去の報告によれば、second eyeの視力がQOLに強く相関することが示唆されるが、それではsecond eye視力が良好である状況下において、first eyeのみ罹患した状態がQOLに関与するの否か、するならばどのように関与するかについてはよく分かっていない。このような、少なくとも1眼の視力が良好な症例のQOLを検討した報告はない。今回我々は、少なくとも1眼の視力が0.7以上と比較的良好な黄斑疾患症例に対して、VFQ-25日本語版を用いて視覚関連QOLを調査し、その分布と、性別、年齢、および視力との関連について検討した。

B. 研究方法

2003年7月～2005年7月に東京大学医学部附属病院黄斑外来を受診した黄斑疾患(後掲)を有する症例のうち、少なくとも1眼の矯正視力が0.7以上である計55例すなわち男38例、女17例、平均年齢67歳(27-91)の症例に対して、VFQ-25日本語版による調査を行った。調査は25項目および14のオプション項目につき自己記入用紙を用いて回答を得た。自己記入が困難な症例は家族または眼科スタッフが介助した。本調査票の使用に関しては、NPO健康医療評価研究機構に対し、VFQ-25日本語版の使用登録を事前に申請した。VFQ-25のスコアリングについては、各設問(5択式)毎に、解答に既定のスコア(0-100)

を割り付け、回答数の稀少であった「運転」を除く11の各下位尺度毎に割り当てられた設問のスコアを加算平均した。下位尺度およびVFQ-25またはオプション14項目の質問を加えたVFQ-39の相当項目数は別表の通りである。

表：VFQの下位尺度と相当質問項目数

下位尺度	設問数	
	VFQ-25	-39*
全体的健康観	1	2
全体的見え方	1	2
眼痛	2	2
近見視力による行動	3	6
遠見視力による行動	3	5
社会生活機能	2	3
心の健康	4	5
役割制限	2	4
自立	3	4
色覚	1	1
周辺視覚	1	1

解析方法は、①全症例、②61歳以上の症例群、および③60歳以下の症例群に対して、説明変数(性別、年齢、良好眼logMAR視力、および不良眼logMAR視力)および従属変数VFQ下位尺度11項目の各スコア)に関し、(1)VFQ-25スコアでのPearson相関分析、(2)VFQ-39スコアでのPearson相関分析、および(3)ステップワイズ重回帰分析(変数増加方)を行い、少なくとも(1)かつ(3)において $p < 0.05$ の有意な相関を示したものを「関連有り」とした


(倫理面への配慮)

本研究は、東京大学医学部倫理委員会の承認を受けた。対象症例からは文書による同意を得、診療記録の調査におけるプライバシーの保護に特に配慮した。

C. 研究結果


背景疾患は加齢黄斑変性(AMD)およびポリープ状脈絡膜血管症41例、近視性新生血管黄斑症9例、特発性脈絡膜新生血管4例、慢性中心性漿液性網脈絡膜症1例である。視力分布は別図の通りである。

図：視力分布グラフ



図：全症例における年齢と

「心の健康」スコアの分布および回帰直線




①全症例においては、年齢と「心の健康」および「役割制限」スコアに関連を認めた。


②61歳以上症例群においては、いずれの変数間とも関連を認めなかった。

③60歳以下症例群においては、不良眼logMAR視力と「心の健康」および「役割制限」スコアに関連を認めた。


図：全症例における年齢と「役割制限」スコアの分布および回帰直線



図：60歳以下の症例における不良眼logMAR視力と「役割制限」スコアの分布および回帰直線



図：60歳以下の症例における
不良眼logMAR視力と「心の健康」スコアの
分布および回帰直線



D. 考察

過去に、白人の両眼加齢黄斑変性症例における VFQ-25 測定において、年齢と「全体的見え方」、「遠見行動」、「心の健康」、および「役割制限」とが正相関したと報告されている。⁵ 今回の検討では、全症例に関して、同様に年齢と「心の健康」「役割制限」との関連を認めた。少なくとも1眼の視力が良好な黄斑疾患症例において、年齢がQOLに与する可能性が示唆される。

一方、60歳以下の症例に関して、不良眼視力と「心の健康」「役割制限」スコアに関連を認めたが、61歳以上の症例には認めなかった。症例数が少なくさらなる検討を要するが、少なくとも1眼の視力が良好な黄斑疾患症例のうち、年齢が比較的若い症例は不良眼視力がQOLに与する可能性が示唆される。

E. 結論

少なくとも1眼の視力が0.7以上の黄斑疾

患症例に対し、VFQ-25日本語版を用いて視覚関連QOLを調査したが、年齢と、「心の健康」および「役割制限」との関連を認め、また60歳以下の症例においては不良眼視力と「心の健康」および「役割制限」との関連を認めた。

F. 健康危険情報

なし

G. 研究発表

1. 論文発表

なし

2. 学会発表

小畑 亮 他. 片眼視力が良好な黄斑疾患症例の視覚関連 quality of life. 第59回日本臨床眼科学会、札幌、2005

H. 知的財産権の出願・登録状況

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

I. 参考文献

1. Nippon Ganka Gakkai Zasshi 108: 770-807,2004.
2. Nippon Ganka Gakkai Zasshi 108: 368-374,2004.
3. Nippon Ganka Gakkai Zasshi 108: 368-374,2004.
4. Am J Ophthalmol 138: 91-108, 2004.
5. Am J Ophthalmol 138: 91-108, 2004.

27. 家兔眼での新しい加齢黄斑変性モデル

安川 力、高瀬綾恵、小椋祐一郎
(名古屋市大)

研究要旨 加齢黄斑変性の確実な危険因子である「加齢」により眼内にまず起こる変化は、網膜色素上皮 (RPE: retinal pigment epithelium) 細胞内へのリポフスチンの蓄積である。我々は、リポフスチン内に多く存在すると考えられる最終糖化産物 (AGE: advanced glycation end products) からなる微粒子を作製し家兔の網膜下に注入することにより、新しい加齢黄斑変性モデルを開発した。AGE 微粒子を網膜下に投与 1 週目には RPE 細胞の貪食作用により RPE 内に移行しており、リポフスチン蓄積と類似した状態となった。コントロール微粒子では、移植 8 週後、移植部位に軽度の蛍光漏出を認めたが、12 週目には漏出は軽減し、組織的に脈絡膜新生血管組織は認められなかった。一方、AGE 微粒子投与群では、4 週目にはドルーゼン様沈着物をコントロール微粒子群に比較して有意に認めるようになり、組織的にはドルーゼン様沈着物の他に、時に網膜下および RPE 下の脈絡膜新生血管、遊走してきたマクロファージを認めた。このリポフスチン蓄積模倣による家兔眼加齢黄斑変性モデルは、リポフスチンの病態への関わりを解明する上で有用であると考えられた。

A. 研究目的

加齢黄斑変性 (AMD) は欧米諸国では成人失明の主要原因であり、近年、我が国でも増加傾向にある。病態については不明な点が多い。現在、光線力学療法を初めとして、様々な治療が行われているが、一度低下した視力を改善させることは難しい場合が多く、今後、より早期に行える新しい治療法の開発が望まれるが、そのためにも病態を解明することが重要である。AMD の確実な危険因子は「加齢」であるが、「加齢」によりまず眼内に起こる変化は、網膜色素上皮 (RPE) 内へのリポフスチンの沈着である。我々は、リポフスチンの主要成分と考えられる最終糖化産物 (AGE) の反応を利用してリポフスチンを模倣した微粒子を作製し、これを家兔の網膜下に注入することにより、

AMD に類似した変化が誘導できるか検討した。

B. 研究方法

トルエン内でアルブミン水溶液のエマルジョンを形成させた後、AGE 反応の中間産物であるグリコールアルデヒドに反応させて、AGE 微粒子を作製した。グルタルアルデヒドを利用してコントロール微粒子も作製した。これらを家兔の網膜下に経強膜・経網膜的に注入した。これらの眼を術後 1 週、4 週、8 週、12 週に蛍光眼底撮影 (FA)、眼底検査を施行、また摘出した眼球を組織的に検討した。対照群としては、コントロール微粒子の他に、アルブミン水溶液、水溶性 AGE を注入して、同様の観察を行った。

(倫理面への配慮)

動物の取り扱いについては、Association for Research and Vision in Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research に従って実行された。

C. 研究結果

アルブミン水溶液を家兔の網膜下に注入した眼においては、注入部の色素のむらを認めるのみであった。水溶性 AGE を注入した眼においては、術後 4 週目には FA にて過蛍光点を認めたが、徐々に改善した。組織的には視細胞の萎縮を認めたが RPE に構造上の異常を認めなかった。コントロール微粒子、AGE 微粒子共に、術後 1 週目には RPE の貪食作用により RPE の細胞内に移行したが、コントロール微粒子は時間とともに消退する傾向を認めた。微粒子は RPE の基底側部側に移動。ブルッフ膜に向かって排泄される傾向を示したが、AGE 微粒子は術後 12 週目においても RPE 内に多く留まり、リポフスチンの蓄積と類似した状態を得た。コントロール微粒子注入眼では、術後 4 週、8 週において、FA にて過蛍光点を認めたが、1 2 週目には消退した。組織的には、網膜の構造の乱れ、RPE の脱色素を認めたが、RPE の一層の構造は保たれていた。それに比べ、AGE 微粒子注入群では、4 週目から蛍光漏出を認める場合や、1 2 週目になって蛍光漏出を認める場合があり、組織的に術後 4 週目での蛍光漏出は classic 脈絡膜新生血管 (CNV)、術後 1 2 週目になって認める蛍光漏出部は occult CNV に相当すると考えられた。術後 4 週において、AGE 微粒子注入群では、コントロール微粒子注入群に

比較して有意にドルーゼン様の沈着物を認めた。水溶液注入眼ではドルーゼンは形成されなかった。AGE 微粒子注入群において、組織的に CD68 陽性のマクロファージと考えられる細胞が AGE 微粒子を含んだ RPE 細胞の基底側部に遊走している像を認めた。

D. 考察

AGE 微粒子は RPE 内に長く留まり、その結果として、ドルーゼン、時にマクロファージの遊走、CNV の発生を認めると考えられた。このモデルにおいて認めた classic CNV は、術後早期より発生したため、手術侵襲、大量の微粒子が網膜下に存在することにより物理化学的な影響により、炎症性に誘導された可能性が高いが、occult CNV に関しては、術後 1 2 週目などに発生を認め、RPE に滞留する微粒子の影響により発生したと考えられた。

E. 結論

以上の結果より、AMD におけるリポフスチンの蓄積の影響が示唆された。この新しい家兔加齢黄斑変性モデルは、AMD の病態におけるリポフスチンの役割を検討する上で有用であり、ドルーゼンなどの病態の理解にも役立つと考えられた。

F. 健康危険情報

なし

G. 研究発表

1. 論文発表

1. Yasukawa T et al: Drug delivery systems for vitreoretinal diseases. *Prog Retin Eye Res* 23:253-281, 2004.

2. 学会発表

1. Yasukawa T et al: A new model of age-related macular degeneration induced by advanced glycation end products. The Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, Florida, 2002.
2. Yasukawa T et al: A new model of age-related macular degeneration induced by advanced glycation end products. 1st Leipzig Research Festival for Life Sciences, Leipzig, Germany, 2002.
3. Yasukawa T et al: Possible role of advanced glycoxidation products accumulated in retinal pigment epithelial cells in the pathology of age-related maculopathy. The Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, Florida, 2003.
4. Yasukawa T et al: Implication of intracellular glycoxidation products in age-related macular degeneration (AMD): a novel AMD model. Workshop of the DFG, Age-Related Macular Degeneration, Baden-Baden, Germany, 2003.
5. Yasukawa T et al: Implication of Intracellular Glycoxidation Products in Age-Related Macular Degeneration (AMD): A Novel AMD Model. 2nd Leipzig Research Festival for Life Sciences, Leipzig, Germany, 2003.
6. Yasukawa T et al: Basal deposits of

undigested material may disturb possible role of macrophages and choriocapillaris in the maintenance of Bruch's membrane, leading to drusen formation. 24th meeting of the Club Jules Gonin, Athens, Greece, 2004.

7. 安川 力: 加齢黄斑変性の病態. PDT 研究会, 名古屋市, 2005.

H. 知的財産権の出願・登録状況

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

I. 参考文献

1. Hageman GS et al: An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. *Prog Retin Eye Res* 20: 705-732, 2001.
2. Schutt F et al: Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. *Invest Ophthalmol Vis Sci* 44 : 3663-3668, 2003.
3. Sparrow JR et al: RPE lipofuscin and its role in retinal pathobiology. *Exp Eye Res* 80: 595-606, 2005.

28. ラット脈絡膜新生血管モデルを用いた光線力学的治療における

細胞死のメカニズム

松原明久¹⁾、中澤 徹²⁾、野田航介²⁾、
Evangelos S Gragoudas²⁾、Joan W Miller²⁾、小椋祐一郎¹⁾
(¹⁾ 名古屋市大、²⁾ Massachusetts Eye and Ear Infirmary)

研究要旨 ラット脈絡膜新生血管モデルに PDT を施行し、アポトーシスの機構と PI3-K/Akt 経路の関与について検討した。実験動物は Brown-Norway ラットを使用し、CNV はレーザー光凝固により作成した。verteporfin を 3, 6, 12 mg/m² の濃度で静注し、15 分後に照射出力 600mW/cm²、光照射エネルギー量 25 J/cm² の条件で PDT を行った。CNV 中のアポトーシス細胞は TUNEL 法で、カスパーゼ 3, 9 の活性は免疫染色法により検出した。リン酸化 Akt は免疫染色法と Western blot 法で検出し、Akt の活性化には IGF-1 (5, 10 μ g) を、不活性化には wortmannin (12.5 μ M) を硝子体内注入した。CNV 中の TUNEL 陽性細胞は PDT 後 3 時間で増加し始め、6 時間後に最大となった。Akt の脱リン酸化は PDT 1 時間以内に始まり、その後カスパーゼが活性化された。CNV 中のカスパーゼ 9 陽性細胞は TUNEL 陽性を示した。IGF-1 は有意に Akt をリン酸化し、TUNEL 陽性細胞数を減少させた。また、その効果は wortmannin により減じられた。ラット CNV モデルに対する PDT はカスパーゼ介在性のアポトーシスをきたし、その制御に Akt の脱リン酸化が関与していることが示唆された。

A. 研究目的

脈絡膜新生血管 (choroidal neovascularization, CNV) に対して光感受性物質 verteporfin をもちいた光線力学的治療 (photodynamic therapy, PDT) が広く行われているが、そのメカニズムに関しては不明な点が多い。近年、PDT により CNV 中の細胞がアポトーシスをきたすことが報告されている^{1,2)}。今回我々はラット脈絡膜新生血管モデルに PDT を施行し、アポトーシスの機構と PI3-K/Akt 経路の関与について検討した。

B. 研究方法

実験動物は Brown-Norway ラットを使用し、CNV はレーザー光凝固により作成した。verteporfin を 3, 6, 12 mg/m² の濃度で静注し、15 分後に照射出力 600mW/cm²、光照射エネルギー量 25 J/cm² の条件で PDT を行った。CNV 中のアポトーシス細胞は TUNEL 法で、カスパーゼ 3, 9 の活性は免疫染色法により検出した。リン酸化 Akt は免疫染色法と Western blot 法で検出し、Akt の活性化には IGF-1 (5 μ g) を、不活性化には wortmannin (12.5 μ M) を硝子体内注入した。

(倫理面への配慮)

動物実験の取り扱いには ARVO に準じた。

C. 研究結果

CNV 中の TUNEL 陽性細胞は PDT 後 3 時間で増加し始め、6 時間後に最大となった。Akt の脱リン酸化は PDT1 時間以内に始まり、その後カスパーゼが活性化された。CNV 中のカスパーゼ 9 陽性細胞は TUNEL 陽性を示した。IGF-1 は有意に Akt をリン酸化し、TUNEL 陽性細胞数を減少させた。また、その効果は wortomannin により減じられた。




図 1 CNV 中の TUNEL 陽性細胞の割合 (%)




図 2 CNV 中の p-Akt, TUNEL 陽性細胞の割合 (%)




図 3 IGF-1 (5, 10 μ g)、wortomannin (12.5 μ M) を硝子体内注入した時の CNV 中の TUNEL 陽性細胞の割合 (%)

D. 考察

Akt の脱リン酸化は PDT1 時間以内に始まり、3 時間以内にカスパーゼが活性化された。CNV 中のカスパーゼ 9 陽性細胞は TUNEL 陽性を示したことから、PDT はカスパーゼ介在性のアポトーシスをきたしうると考えられた。IGF-1 は Akt をリン酸化して TUNEL 陽性細胞数を減少させ、その効果は wortomannin により減じられたことから、PDT 後の Akt の脱リン酸化がアポトーシスの一因と考えられた。

E. 結論

ラット CNV モデルに対する PDT はカスパーゼ介在性のアポトーシスをきたし、その制御に Akt の脱リン酸化が関与していることが示唆された。

F. 健康危険情報

なし

G. 研究発表

1. 論文発表

なし

2. 学会発表

なし

H. 知的財産権の出願・登録状況

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

I. 参考文献

1. Reem Z. Renno, Francois C. Delori, Robin A. Holzer, Evangelos S. Gragoudas, and Joan W. Miller :
Photodynamic Therapy Using Lu-Tex Induces Apoptosis In Vitro, and Its Effect Is Potentiated by Angiostatin in Retinal Capillary Endothelial Cells
Invest. Ophthalmol. Vis. Sci. 41: 3963-3971, 2000.
2. T.A. Young, M.B. Pantcheva, E.J. Connolly, M.S. Mandelcorn, C.I. Whiteside, C.L. Grosskreutz, E.S. Gragoudas, and J.W. Miller :
Apoptosis in Acute Photodynamic Therapy of Choroidal Neovascularization in the Rat Model.
ARVO. 44: E-Abstract 3932, 2003.

Protective effect of polyethylene glycol-superoxide dismutase on leukocyte dynamics in rat retinal microcirculation under lipid hydroperoxide-induced oxidative stress

Akihisa Matsubara^{a,*}, Kazushi Tamai^a, Yoshito Matsuda^a, Yuji Niwa^a, Hiroshi Morita^a, Kazuyuki Tomida^a, Donald Armstrong^b, Yuichiro Ogura^a

^aDepartments of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

^bDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, FL and Oxidative Stress Associates Inc., Alachua, FL, USA

Received 2 November 2004; accepted in revised form 25 January 2005

Available online 2 March 2005

Abstract

The levels of lipid hydroperoxide (LHPs) in vitreous are elevated in a variety of retinal disorders. Recently, we have shown that increased levels of LHPs in the vitreous enhanced leukocyte-endothelium interaction in the retina, which should contribute to the initial disturbance of the retinal microcirculation. Based upon the previous work, the purpose of the present study was to investigate the effect of polyethylene glycol-superoxide dismutase (PEG-SOD), one of the important enzyme antioxidants, on leukocyte-endothelial interaction in the retinal microcirculation under LHP-induced oxidative stress. Male Brown-Norway rats weighing approximately 250 g were used. LHP(18:2) was made from linoleic acid (LA) with lipoxygenase and 10 µg of LHP dissolved in 5 µl of sodium borate buffer (SBB, 0.02 M) was slowly injected into the vitreous using a 33-gauge needle. PEG-SOD (5000 units/kg) was given intravenously 5 min before LHP injection. At 2, 4, 6, 12, 24 and 48 hr after the vitreous injections, we evaluated the number of rolling leukocytes along the major retinal veins and the number of leukocytes that accumulated in the retinal microvasculature with acridine orange digital fluorography. In LHP-treated rats, leukocyte rolling along the major retinal veins was maximal at 6 hr after LHP injection. The number of rolling leukocytes in the PEG-SOD-treated rats was decreased to 5.5% of those in the LHP-treated rats at 6 hr after LHP injection ($P < 0.01$). No rolling leukocytes were observed in either control or vehicle-treated eyes. The number of accumulated leukocytes in LHP-treated eyes started to increase at 12 hr, and peaked at 24 hr which was significantly higher than in both control and vehicle-treated eyes ($P < 0.01$). The number of accumulated leukocytes in the PEG-SOD-treated rats was reduced by 88.0% at 24 hr ($P < 0.01$). Intravenous injection of PEG-SOD significantly inhibited the leukocyte rolling and its accumulation under LHP-induced oxidative stress. These results suggest that PEG-SOD might attenuate various retinal microcirculatory disorders associated with LHP.

© 2005 Elsevier Ltd. All rights reserved.

Keywords: lipid polyethylene-hydroperoxide; leukocyte; glycol-superoxide dismutase; retinal microcirculation

1. Introduction

Free radical and lipid peroxide formation, which can cause oxidative stress-induced damage to cell membranes,

are initiated by various factors. As the eye is always exposed to initiators such as oxygen, light, ultraviolet ray and x-irradiation, the relationship between free radicals and ocular diseases has attracted much attention. Many studies have suggested important roles of free radicals and lipid peroxides in various ocular diseases including keratitis, cataract, uveitis, retinal degeneration, diabetic retinopathy, retinopathy of prematurity and retinal ischemic diseases (Lakatos et al., 1982; Sery and Petrillo, 1984; Bhuyan et al., 1986; Armstrong et al., 1992; Alio et al., 1995; Spaide et al., 1999).

The retina contains a high proportion of polyunsaturated fatty acids, which are susceptible to lipid peroxidation.

* Corresponding author. Present address: Dr Akihisa Matsubara, Ten Emerson Place-20A, Boston, MA 02114, USA.

E-mail addresses: akihisa_matsubara@meei.harvard.edu (A. Matsubara), kazutamai@aol.com (K. Tamai), osa@aol.com (D. Armstrong), ogura@med.nagoya-cu.ac.jp (Y. Ogura).

Lipid hydroperoxide (LHPs) derived from oxidized unsaturated fatty acids are prominent intermediates of propagative reactions induced by activated species such as hydroxyl radical, lipid oxyl or peroxy radicals, singlet oxygen, and peroxyxynitrite (Girotti, 1998). It is also known that lipid peroxidation injury to the endothelial cell membrane provides a signal or serves as a marker that can be recognized by circulating polymorphonuclear leukocytes (Del Maestro et al., 1981). Patel et al. (1991) reported that reactive oxygen species like H_2O_2 and LHP increased the expression of P-selectin and the adherence of neutrophils to endothelial cells *in vitro*. Recently, we have shown that oxidative stress induced by 18:2 LHP injection in the vitreous enhanced leukocyte-endothelium interaction in the retinal microcirculation *in vivo* using acridine orange digital fluorography (Tamai et al., 2002).

LHP is associated with a variety of retinal disorders such as diabetic retinopathy (Armstrong et al., 1992; Augustin et al., 1993), Eales' disease (Bhooma et al., 1997), proliferative vitreoretinopathy (Boker et al., 1994), retinopathy of prematurity (Lakatos et al., 1982), and age-related macular degeneration (Spaide et al., 1999). In fact, in the vitreous samples from patients with proliferative diabetic retinopathy (Augustin et al., 1993; Verdejo et al., 1999) or proliferative vitreoretinopathy (Boker et al., 1994; Verdejo et al., 1999), LHP levels were shown to be significantly elevated. In those patients, antioxidant activity was reduced compared with normal counterparts (Verdejo et al., 1999). It was demonstrated that levels of superoxide dismutase (SOD), one of the important enzyme antioxidants were notably reduced in diabetic patients (Kernell et al., 1992) and patients with Eales' disease which induces retinal vascular occlusion, inflammation and neovascularization (Sulochana et al., 1999). Therefore, we hypothesize that increasing the levels of SOD may reduce retinal microcirculatory disorders associated with LHP. In this study, we have investigated the effect of intravenous injection of SOD on rat retinal microcirculatory disorders under LHP-induced oxidative stress in terms of leukocyte dynamics *in vivo*. We used here polyethylene glycol-conjugated superoxide dismutase (PEG-SOD) that has a longer half-life in plasma (>30 hr) than native SOD and has been proven to be effective against ischemic conditions (Pyatak et al., 1980; Tamura et al., 1988; Chi et al., 1989).

2. Materials and methods

2.1. Animal model

Male Brown–Norway rats weighing approximately 250 g were used. Only one eye of each rat was used. Rats were anesthetized with a mixture (1:1) of xylazine hydrochloride (4 mg/kg) and ketamine hydrochloride (10 mg/kg). The pupils were dilated with 0.5% tropicamide and 2.5% phenylephrine hydrochloride. LHP (18:2) was made from

linoleic acid (LA) with lipoxygenase and 10 μ g of LHP dissolved in 5 μ l of sodium borate buffer (SBB, 0.02 M) was slowly injected into the vitreous using a 33-gauge needle (Browne and Armstrong, 2002). Vehicle-treated rats were given the same amount of LA dissolved in 5 μ l of SBB. PEG-SOD-treated rats were injected intravenously with 5000 units/kg of PEG-SOD (Sigma-Aldrich) 5 min before LHP injection. All experiments were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

2.2. Acridine orange digital fluorography

Acridine orange digital fluorography was performed as previously described (Kimura et al., 1995; Nishiwaki et al., 1995). In this technique, a scanning laser ophthalmoscope (Rodenstock Instrument), coupled with a computer-assisted image analysis system, makes continuous high-resolution images of the fundus stained with the metachromatic fluorochrome, acridine orange (AO; Wako Pure Chemical), which emits a green fluorescence when it interacts with DNA. The spectral properties of AO-DNA complexes are very similar to those of sodium fluorescein, with an excitation maximum at 502 nm and an emission maximum at 522 nm (Darzynkiewicz and Kapuscinsky, 1990). An argon blue laser was used as the illumination source, with a regular emission filter for fluorescein angiography.

Immediately before acridine orange digital fluorography, rats were anesthetized, and the pupils were dilated. A contact lens was used to retain corneal clarity throughout the experiment. Each rat had a catheter inserted into the tail vein, and was placed on a stereotaxic platform. Body temperature was maintained at 38 ± 0.5 °C. Immediately after AO (0.1% solution in saline) solution was infused intravenously, leukocytes stained selectively among circulating blood cells were observed with the scanning laser ophthalmoscope. Nuclei of vascular endothelial cells were also stained. AO was injected continuously through the catheter for 1 min at a rate of 1 ml/min. The fundus was observed to evaluate the leukocyte dynamics in the retinal microcirculation for 5 min after AO injection in a 40° field. AO easily infiltrates through vessel walls and diffuses into the retina due to its membrane permeability. Accordingly, a few minutes after AO injection was completed, fluorescence of circulating leukocytes was faint, due to washout. In contrast, leukocytes that had been trapped in the retinal microcirculation remained fluorescent for approximately 2 hr, being recognized as distinct fluorescent dots 30 min after AO injection. At 30 min after the injection of AO, the fundus was observed again to determine leukocyte accumulation in the retinal microcirculation. The obtained images were recorded on digital videotape at a rate of 30 frames/sec for further image analysis. After the experiment, rats were killed with an anesthetic overdose, and the eye was enucleated to determine a calibration factor with which to

convert values measured on a computer monitor (in pixels) into real values (in μm).

2.3. Experimental design

Acridine orange digital fluorography was performed at 2, 4, 6, 12, 24 and 48 hr after vitreous injections in LA and LHP-treated rats. In PEG-SOD treated-rats, it was held at 6, 12, 24 and 48 hr after LHP injections. Non-operated rats were used as controls. Five different rats were randomly selected and used at each time point in each group. We evaluated the number of rolling leukocytes along the major retinal vessels, the number of leukocytes accumulated in the retinal microcirculation, and the diameters of major retinal vessels in a masked manner.

2.4. Image analysis

The digital video recordings were analysed with an image analysis system, described in detail elsewhere (Kimura et al., 1995; Nishiwaki et al., 1995) with a slight modification. In brief, we used a computer equipped with software (DVgate, SONY) which enters the digital images in real time (30 frames/sec) to 640 horizontal and 480 vertical pixels with an intensity resolution of 256 steps into a personal computer.

Rolling leukocytes were defined as leukocytes that moved at a velocity much slower than that of free-flowing leukocytes. The process of differentiating rolling leukocytes from free-flowing leukocytes has been described in a previous article (Tsuji-kawa et al., 1998). In brief, leukocytes rolling along the major retinal veins were easily recognized on the video monitor, because even the fastest rolling leukocyte moved almost 300 times more slowly than the average for free-flowing leukocytes. Since no leukocytes with intermediate velocity were observed, it was not difficult to distinguish rolling leukocyte from free-flowing leukocytes. Their numbers were calculated from the number of rolling cells passing a fixed line in all major veins (4–7 veins) at a distance of 1 disk diameter from the center of the optic disc per minute. The average number of rolling leukocytes in individual major veins was used as the value for each rat.

The number of leukocytes accumulated in the retinal microcirculation was evaluated at 30 min after AO injection. The number of fluorescent dots in the retina within 8 areas of 100 pixels square at a distance of 1 disk diameter from the edge of the optic disk was counted. The average density of leukocytes in individual areas was used as the value for each rat.

The diameters of major retinal vessels were measured at 1 disk diameter from the center of the optic disk in monochromatic images recorded before AO injection. Each vessel diameter was calculated in pixels as the distance between the half-high points determined separately on each side of the density profile of the vessel image and converted into real values using the calibration factor. The averages of

the individual arterial and venous diameters were used as the arterial and venous diameters for each rat.

2.5. Statistical analysis

All values are presented as mean \pm s.d.. Data were compared by ANOVA, with post hoc comparisons tested using the Bonferroni procedure. Probabilities of $P < 0.05$ were considered to be statistically significant.

3. Results

3.1. Leukocyte rolling

Immediately after AO was infused, many free-flowing leukocytes were visualized. No rolling leukocytes were observed along the major retinal veins in control and LA-treated rats. In all eyes injected with LHP, a few leukocytes rolling along major retinal veins were observed initially at 2 hr after the injection. The number peaked at 110.6 ± 11.4 cells/min at 6 hr after the injection and decrease thereafter. The number of rolling leukocytes was significantly less in PEG-SOD-treated rats than in LHP-treated rats ($P = 0.0104$). In PEG-SOD-treated rats, the number of rolling leukocytes was 6 ± 0.3 cells/min at 6 hr after LHP injection, which was significantly reduced by 94.5% compared with that in LHP-treated rats ($P < 0.01$) (Fig. 1). There weren't any rolling leukocytes along retinal arteries in all groups throughout the experiments.

3.2. Leukocyte Accumulation in the retinal microcirculation

Leukocytes accumulated in the retinal microcirculation were recognized as distinct fluorescent dots 30 min after AO injection, although no circulating leukocytes fluoresced (Fig. 2). In LA-treated rats, a few leukocytes could be recognized at any time point. The number of accumulated




Fig. 1. Time course of the number of rolling leukocytes in major veins. Values are mean \pm s.d. * $P < 0.01$, compared with LA-treated rats. † $P < 0.01$, compared with LHP-treated rats. Five different rats were used at each time point in each group.




Fig. 2. Representative fundus images of leukocyte accumulation at 24 hr after vitreous injection. Leukocyte accumulated in the retina were observed as fluorescent dots 30 min after acridine orange injection. A small number of leukocytes could be found in control (A) and LA-treated rats (B). In LHP-treated rats, increasing number of leukocytes accumulated at 24 hr after LHP injection (C). Significant reduction of leukocyte accumulation was seen in PEG-SOD-treated rats (D).

leukocytes in LHP-treated eyes started to increase at 12 hr (152.2 ± 37.3 cells/mm²), and peaked at 24 hr (919.0 ± 223.1 cells/mm²) which was significantly higher than in both control and LA-treated eyes (21.3 ± 5.0 and 45.3 ± 9.8 cell/mm², respectively, $P < 0.01$). The number of accumulated leukocytes was significantly less in PEG-SOD-treated rats than in LHP-treated rats ($P = 0.0105$). With the treatment of PEG-SOD, the number of accumulated leukocytes was significantly reduced by 73.7% at 12 hr ($P < 0.01$) and 88.0% at 24 hr ($P < 0.01$) after LHP injections (Fig. 3).

3.3. Diameters of major retinal vessels

In arteries, a slight vasodilation appeared to occur at 4–24 hr after LHP injection; however, no significant differences were observed among any experimental groups (Fig. 4(A)). In veins, significant vasodilation was observed at 6–24 hr after LHP injection ($P < 0.05$, versus LA-treated rats). The vasodilation peaked at 12 hr after LHP injection (122% in LHP-treated rats, $P < 0.05$, versus LA-treated rats) and subsided at 48 hr after injection. In PEG-SOD-treated rats, venous vasodilation was significantly suppressed compared with that in LHP-treated rats at 12 hr after LHP injection ($P < 0.05$) (Fig. 4(B)).

4. Discussion

The present study demonstrated *in vivo* that intravenous injection of PEG-SOD significantly suppressed

LHP-induced increase in both leukocyte rolling along the retinal vessels and leukocyte accumulation in the retina. Leukocyte-endothelial interactions are regulated by multi-step processes (Osborn, 1990), with each step mediated by distinct adhesion like molecules (Lawrence and Springer, 1991). Leukocyte rolling is the first step in a cascade of events that lead to firm adhesion and transmigration through the endothelium. Leukocyte rolling that represents mild adhesion between leukocytes and endothelial cells is induced mostly by the selectin family at the early stage, and then the strong adhesion is induced because of up-regulation of CD11/CD18b and activation of ICAM-1. P-selectin is thought to play an essential role in initial rolling during an inflammatory




Fig. 3. Time course of the number of leukocytes accumulated in the retina after vitreous injection. Values are mean \pm s.d. * $P < 0.01$, compared with LA-treated rats. † $P < 0.01$, compared with LHP-treated rats. Five different rats were used at each time point in each group.




Fig. 4. Time course of major retinal arterial (A) and venous, (B) diameters after vitreous injection. Values are mean \pm s.d. * $P < 0.05$, compared with LA-treated rats. † $P < 0.05$, compared with LHP-treated rats. Five different rats were used at each time point in each group.

reaction (Lawrence and Springer, 1991). Many studies have demonstrated that inhibition of P-selectin significantly reduced leukocyte rolling (Tsuji-kawa et al., 1999; Matsubara et al., 2000).

Oxygen-derived free radicals are known to enhance leukocyte-endothelial adherence. Patel et al. (1991) reported that reactive oxygen species like H_2O_2 and LHP increased the expression of P-selectin and the adherence of neutrophils to endothelial cells in vitro. Reactive oxygen species also induce expression of ICAM-1 in endothelial cells (Chiu et al., 1997). LHPs have been proposed as mediators or sec messengers, whereby they induce gene expression and up-regulate various cytokines (Suzuki et al., 1997). Armstrong et al. (1998) reported that 18:2 LHP injected in the vitreous of albino rabbits started to increase the concentration of various cytokines (TNF- α , IL-1 α , PDGF and VEGF) in the retina at early periods (3–12 hr). In the presence of TNF- α and IL-1, expression of adhesion molecules including ICAM-1 is increased and leukocyte-endothelial adhesion is induced in vitro (Morzycki et al., 1990; Hubbard and Rothlein, 2000), and thereby leukocyte-endothelium interaction is enhanced in addition to the direct action of LHP. Previously, we have reported that increased LHP levels in the vitreous enhanced leukocyte-endothelial interaction in the retinal microcirculation in vivo (Tamai et al., 2002).

Many studies have shown beneficial effects of SOD for ischemic disorders such as myocardial and cerebral ischemia-reperfusion (Naslund et al., 1986; Schettini et al., 1989). However, maintaining appropriate plasma SOD levels is difficult because of the short life of native SOD (half-life time: 6–10 min) (Galina-nes et al., 1992). In the present study, we used long acting SOD covalently linked to polyethylene glycol (PEG-SOD), that has been reported to extend the plasma half-life of SOD activity to more than 30 hr (Pyatak et al., 1980; Tamura et al., 1988; Chi et al., 1989).

We found that PEG-SOD treatment significantly inhibited both rolling and accumulation of leukocytes in the retinal microcirculation using acridine orange digital fluorography. Akeo et al. (1996) reported that the damage of the RPE cells exposed by LHP was minimized in a dose-dependent manner after 24 and 48 hr addition of SOD in vitro. As SOD is a well-known enzyme which specifically reduces superoxide (O_2^-), our results suggest that superoxide constitutes an important step in the transduction of the LHP-mediated increase in leukocyte-endothelial cell interaction observed in vivo. Inflammatory conditions and proinflammatory cytokines are also known to stimulate production of reactive oxygen species in endothelial cells and blood vessels (Okada et al., 1998; Rahman et al., 1998; Gunnett et al., 2002). Xanthine oxidase, which produces superoxide in response to proinflammatory cytokines in cultured cells (Page et al., 1998), appears to be an important source of superoxide in vessels under pathological conditions like hypercholesterolemia, atherosclerosis (Graier et al., 1998), and hypertension (Suzuki et al., 1998). Injected LHP in the vitreous generates various cytokines (TNF- α , IL-1 α , PDGF and VEGF) in the retina (Armstrong et al., 1998). TNF- α causes xanthine dehydrogenase-to-xanthine oxidase conversion in rat endothelial cells, which would result in the production of superoxide (Friedl et al., 1989; Kapp et al., 1989). TNF- α could also directly stimulate human neutrophils to produce superoxide. We speculate that LHP injected in the vitreous may sensitize retinal tissue initially and cause preinflammatory conditions, and thereby, superoxide is generated secondarily.

Several reports have showed that exogenous SOD could inhibit leukocyte-endothelial cell interaction (Lehr et al., 1992; Morita et al., 1995). Akgür et al. (2000) quantified P-selectin expression in a murine model of hemorrhage-resuscitation by use of the dual-radiolabeled monoclonal antibody technique and found that either administration of exogenous SOD to wild-type mice or genetic

overexpression of SOD resulted in a significant attenuation of hemorrhage-resuscitation-induced P-selectin expression. Yang et al. (2003) reported that endothelial cells obtained from the aorta of transgenic mice overexpressing Cu, ZnSOD showed significantly less expression of intercellular adhesion molecule-1 (ICAM-1) by using enzyme-linked immunosorbent assay. Therefore, attenuation of adhesion molecule expression by SOD is considered to be linked to decreased leukocyte adhesion.

In the present study, venous vasodilation in PEG-SOD-treated rats was significantly suppressed at 12 hr after vitreous injection, compared with that in LHP-treated rats. Increased production of nitric oxide (NO) may be responsible for the vasodilation after LHP injection. As SOD has been reported to protect against the induction of NO in activated microglial cells (Chang et al., 2001), inhibition of NO production by SOD might prevent venous vasodilation.

Many experimental studies have suggested that preventing leukocyte participation attenuates retinal damage in ischemia-reperfusion injury (Strachan et al., 1992; Tsujikawa et al., 1999; Matsubara et al., 2000). However, further studies are needed to assess whether attenuating leukocyte infiltration contributes to maintenance of retinal function under LHP-induced oxidative stress.

In conclusion, the present study has demonstrated an inhibitory effect of PEG-SOD on enhanced leukocyte-endothelial interaction under LHP-induced oxidative stress in the rat retina. The results suggest that PEG-SOD might attenuate various retinal microcirculatory disorders related to oxidative stress.

References

- Akeo, K., Hiramitsu, T., Kanda, T., Karasawa, Y., Okisaka, S., 1996. Effects of superoxide dismutase and catalase on growth of retinal pigment epithelial cells in vitro following addition of linoleic acid or linoleic acid hydroperoxide. *Ophthalmic Res.* 28, 8–18.
- Akgur, F.M., Brown, M.F., Zibari, G.B., McDonald, J.C., Epstein, C.J., Ross, C.R., Granger, D.N., 2000. Role of superoxide in hemorrhagic shock-induced P-selectin expression. *Am. J. Physiol. Heart. Circ. Physiol.* 279, H791–H797.
- Alio, J.L., Ayala, M.J., Mulet, M.E., Artola, A., Ruiz, J.M., Bellot, J., 1995. Antioxidant therapy in the treatment of experimental acute corneal inflammation. *Ophthalmic Res.* 27, 136–143.
- Armstrong, D., Abdella, N., Salman, A., Miller, N., Rahman, E.A., Bojanczyk, M., 1992. Relationship of lipid peroxides to diabetic complications. Comparison with conventional laboratory tests. *J. Diabetes Complications* 6, 116–122.
- Armstrong, D., Ueda, T., Ueda, T., Ajada, A., Browne, R., Fukkuda, S., Spengler, R., Chou, R., Hartnett, M., Buch, P., Dandona, P., Sasisekharan, R., Dorey, C.K., 1998. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor- α , vascular endothelial growth factor and platelet-derived growth factor. *Angiogenesis* 2, 93–104.
- Augustin, A.J., Breipohl, W., Boker, T., Lutz, J., Spitznas, M., 1993. Increased lipid peroxide levels and myeloperoxidase activity in the vitreous of patients suffering from proliferative diabetic retinopathy. *Graefes. Arch. Clin. Exp. Ophthalmol.* 231, 647–650.
- Bhooma, V., Sulochana, K.N., Biswas, J., Ramakrishnan, S., 1997. Eales' disease: accumulation of reactive oxygen intermediates and lipid peroxides and decrease of antioxidants causing inflammation, neovascularization and retinal damage. *Curr. Eye Res.* 16, 91–95.
- Bhuyan, K.C., Bhuyan, D.K., Podos, S.M., 1986. Lipid peroxidation in cataract of the human. *Life Sci.* 38, 1463–1471.
- Boker, T., Augustin, A.J., Breipohl, W., Spitznas, M., Lutz, J., 1994. Increased lipid peroxide level and myeloperoxidase activity in the vitreous of patients suffering from proliferative vitreoretinopathy. *Graefes. Arch. Clin. Exp. Ophthalmol.* 232, 652–656.
- Browne, R.W., Armstrong, D., 2002. Simultaneous determination of polyunsaturated fatty acids and corresponding monohydroperoxy and monohydroxy peroxidation products by HPLC. *Methods Mol. Biol.* 186, 13–20.
- Chang, S.C., Kao, M.C., Fu, M.T., Lin, C.T., 2001. Modulation of NO and cytokines in microglial cells by Cu/Zn-superoxide dismutase. *Free Radic. Biol. Med.* 31, 1084–1089.
- Chi, L.G., Tamura, Y., Hoff, P.T., Macha, M., Gallagher, K.P., Schork, M.A., Lucchesi, B.R., 1989. Effect of superoxide dismutase on myocardial infarct size in the canine heart after 6 hr of regional ischemia and reperfusion: a demonstration of myocardial salvage. *Circ. Res.* 64, 665–675.
- Chiu, J.J., Wung, B.S., Shyy, J.Y., Hsieh, H.J., Wang, D.L., 1997. Reactive oxygen species are involved in shear stress-induced intercellular adhesion molecule-1 expression in endothelial cells. *Arterioscler. Thromb. Vasc. Biol.* 17, 3570–3577.
- Darzynkiewicz, Z., Kapuscinsky, J., 1990. Acridine orange: a versatile probe of nucleic acids and other cell constituents. In: Melamed, M.R., Lindmo, T., Mendelshn, M.L. (Eds.), *Flow Cytometry and Sorting*. Wiley-Liss, New York, pp. 219–314.
- Del Maestro, R.F., Bjork, J., Arfors, K.E., 1981. Increase in microvascular permeability induced by enzymatically generated free radicals. II. Role of superoxide anion radical, hydrogen peroxide, and hydroxyl radical. *Microvasc. Res.* 22, 255–270.
- Friedl, H.P., Till, G.O., Ryan, U.S., Ward, P.A., 1989. Mediator-induced activation of xanthine oxidase in endothelial cells. *FASEB J.* 3, 2512–2518.
- Galinanes, M., Qiu, Y., Ezrin, A., Hearse, D.J., 1992. PEG-SOD and myocardial protection. Studies in the blood- and crystalloid-perfused rabbit and rat hearts. *Circulation* 86, 672–682.
- Girotti, A.W., 1998. Lipid hydroperoxide generation, turnover, and effector action in biological systems. *J. Lipid Res.* 39, 1529–1542.
- Graier, W.F., Hoebel, B.G., Paltauf-Doburzynska, J., Kostner, G.M., 1998. Effects of superoxide anions on endothelial Ca^{2+} signaling pathways. *Arterioscler. Thromb. Vasc. Biol.* 18, 1470–1479.
- Gunneth, C.A., Heistad, D.D., Faraci, F.M., 2002. Interleukin-10 protects nitric oxide-dependent relaxation during diabetes: role of superoxide. *Diabetes* 51, 1931–1937.
- Hubbard, A.K., Rothlein, R., 2000. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. *Free Radic. Biol. Med.* 28, 1379–1386.
- Kapp, A., Zeck-Kapp, G., Blohm, D., 1989. Human tumor necrosis factor is a potent activator of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: comparison with human lymphotoxin. *J. Invest. Dermatol.* 92, 348–354.
- Kernell, A., Lundh, B.L., Marklund, S.L., Skoog, K.O., Bjorksten, B., 1992. Superoxide dismutase in the anterior chamber and the vitreous of diabetic patients. *Invest. Ophthalmol. Vis. Sci.* 33, 3131–3135.
- Kimura, H., Kiryu, J., Nishiwaki, H., Ogura, Y., 1995. A new fluorescent imaging procedure in vivo for evaluation of the retinal microcirculation in rats. *Curr. Eye Res.* 14, 223–228.
- Lakatos, L., Hatvani, I., Oroszlan, G., Karmazsin, L., Matkovics, B., 1982. D-penicillamine in the prevention of retrolental fibroplasia. *Acta Paediatr. Acad. Sci. Hung.* 23, 327–335.
- Lawrence, M.B., Springer, T.A., 1991. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. *Cell* 65, 859–873.

- Lehr, H.A., Becker, M., Marklund, S.L., Hubner, C., Arfors, K.E., Kohlschutter, A., Messmer, K., 1992. Superoxide-dependent stimulation of leukocyte adhesion by oxidatively modified LDL in vivo. *Arterioscler. Thromb.* 12, 824–829.
- Matsubara, A., Tomida, K., Matsuda, Y., Tamai, K., Tashita, A., Jomori, T., Tsujikawa, A., Ogura, Y., 2000. Protective effects of selectin ligands/inhibitor (SKK-60060) against retinal ischemia-reperfusion injury. *Exp. Eye Res.* 71, 283–293.
- Morita, Y., Clemens, M.G., Miller, L.S., Rangan, U., Kondo, S., Miyasaka, M., Yoshikawa, T., Bulkley, G.B., 1995. Reactive oxidants mediate TNF-alpha-induced leukocyte adhesion to rat mesenteric venular endothelium. *Am. J. Physiol.* 269, H1833–H1842.
- Morzycki, W., Sadowska, J., Issekutz, A.C., 1990. Interleukin-1 and tumour necrosis factor alpha induced polymorphonuclear leukocyte-endothelial cell adhesion and transendothelial migration in vitro: the effect of apical versus basal monolayer stimulation. *Immunol. Lett.* 25, 331–340.
- Naslund, U., Haggmark, S., Johansson, G., Marklund, S.L., Reiz, S., Oberg, A., 1986. Superoxide dismutase and catalase reduce infarct size in a porcine myocardial occlusion-reperfusion model. *J. Mol. Cell. Cardiol.* 18, 1077–1084.
- Nishiwaki, H., Ogura, Y., Kimura, H., Kiryu, J., Honda, Y., 1995. Quantitative evaluation of leukocyte dynamics in retinal microcirculation. *Invest. Ophthalmol. Vis. Sci.* 36, 123–130.
- Okada, H., Woodcock-Mitchell, J., Mitchell, J., Sakamoto, T., Marutsuka, K., Sobel, B.E., Fujii, S., 1998. Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. *Circulation* 97, 2175–2182.
- Osborn, L., 1990. Leukocyte adhesion to endothelium in inflammation. *Cell* 62, 3–6.
- Page, S., Powell, D., Benboubetra, M., Stevens, C.R., Blake, D.R., Selase, F., Wolstenholme, A.J., Harrison, R., 1998. Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. *Biochim. Biophys. Acta.* 1381, 191–202.
- Patel, K.D., Zimmerman, G.A., Prescott, S.M., McEver, R.P., McIntyre, T.M., 1991. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. *J. Cell. Biol.* 112, 749–759.
- Pyatak, P.S., Abuchowski, A., Davis, F.F., 1980. Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. *Res. Commun. Chem. Pathol. Pharmacol.* 29, 113–127.
- Rahman, A., Kefer, J., Bando, M., Niles, W.D., Malik, A.B., 1998. E-selectin expression in human endothelial cells by TNF-alpha-induced oxidant generation and NF-kappaB activation. *Am. J. Physiol.* 275, L533–L544.
- Schettini, A., Lippman, R.H., Walsh, E.K., 1989. Attenuation of decompressive hypoperfusion and cerebral edema by superoxide dismutase. *J. Neurosurg.* 71, 578–587.
- Sery, T.W., Pettrillo, R., 1984. Superoxide anion radical as an indirect mediator in ocular inflammatory disease. *Curr. Eye Res.* 3, 243–252.
- Spaide, R.F., Ho-Spaide, W.C., Browne, R.W., Armstrong, D., 1999. Characterization of peroxidized lipids in Bruch's membrane. *Retina* 19, 141–147.
- Strachan, R.D., Kane, P.J., Cook, S., Chambers, I.R., Clayton, C.B., Mendelow, A.D., 1992. Immunosuppression by whole-body irradiation and its effect on oedema in experimental cerebral ischaemia. *Acta. Neurol. Scand.* 86, 256–259.
- Sulochana, K.N., Biswas, J., Ramakrishnan, S., 1999. Eales' disease: increased oxidation and peroxidation products of membrane constituents chiefly lipids and decreased antioxidant enzymes and reduced glutathione in vitreous. *Curr. Eye Res.* 19, 254–259.
- Suzuki, Y.J., Forman, H.J., Sevanian, A., 1997. Oxidants as stimulators of signal transduction. *Free Radic. Biol. Med.* 22, 269–285.
- Suzuki, H., DeLano, F.A., Parks, D.A., Jamshidi, N., Granger, D.N., Ishii, H., Suematsu, M., Zweifach, B.W., Schmid-Schonbein, G.W., 1998. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. *Proc. Natl. Acad. Sci. USA* 95, 4754–4759.
- Tamai, K., Matsubara, A., Tomida, K., Matsuda, Y., Morita, H., Armstrong, D., Ogura, Y., 2002. Lipid hydroperoxide stimulates leukocyte-endothelium interaction in the retinal microcirculation. *Exp. Eye Res.* 75, 69–75.
- Tamura, Y., Chi, L.G., Driscoll Jr., E.M., Hoff, P.T., Freeman, B.A., Gallagher, K.P., Lucchesi, B.R., 1988. Superoxide dismutase conjugated to polyethylene glycol provides sustained protection against myocardial ischemia/reperfusion injury in canine heart. *Circ. Res.* 63, 944–959.
- Tsujikawa, A., Ogura, Y., Hiroshiba, N., Miyamoto, K., Kiryu, J., Honda, Y., 1998. In vivo evaluation of leukocyte dynamics in retinal ischemia reperfusion injury. *Invest. Ophthalmol. Vis. Sci.* 39, 793–800.
- Tsujikawa, A., Ogura, Y., Hiroshiba, N., Miyamoto, K., Kiryu, J., Tojo, S.J., Miyasaka, M., Honda, Y., 1999. Retinal ischemia-reperfusion injury attenuated by blocking of adhesion molecules of vascular endothelium. *Invest. Ophthalmol. Vis. Sci.* 40, 1183–1190.
- Verdejo, C., Marco, P., Renau-Piqueras, J., Pinazo-Duran, M.D., 1999. Lipid peroxidation in proliferative vitreoretinopathies. *Eye* 13 (Pt 2), 183–188.
- Yang, H., Shi, M., Richardson, A., Vijg, J., Guo, Z., 2003. Attenuation of leukocyte-endothelium interaction by antioxidant enzymes. *Free Radic. Biol. Med.* 35, 266–276.

29. ポリープ状脈絡膜血管症 (PCV) に対する

光線力学療法 (PDT) の効果

赤座英里子、森隆三郎、湯沢美都子

(日本大)

研究要旨 目的：ポリープ状脈絡膜血管症 (PCV) に対する光線力学療法 (PDT) の効果を明らかにする。対象および方法：対象はフルオレセイン蛍光造影 (FA) で中心窩に CNV の所見があり、インドシアニングリーン蛍光造影 (IA) で PCV と診断し、PDT を施行した 37 例 37 眼。それらに対し、PDT 施行回数、12 か月後の視力の推移、IA でのポリープ状病巣と異常血管網の変化をしらべた。結果：PDT 施行回数は、1 回が 14 眼、2 回が 11 眼、3 回が 9 眼、4 回が 3 眼であった。視力は、改善 12 眼 (33%)、不変 16 眼 (43%)、悪化 9 眼 (24%) であった。12 か月後の IA で、ポリープ状病巣は全部消失 31 眼 (84%)、異常血管網は、不変 28 眼 (76%) であった。3 眼に残存した異常血管網の辺縁にポリープ状病巣の再発をみとめた。結論：IA で PCV と診断できる場合、PDT は 1 年後の視力の改善、維持に有効であった。PDT によってポリープ状病巣は、容易に消失したが、異常血管網は残存した。残存した異常血管網からポリープ状病巣の再発をみとめる場合があったことから、PDT の有効性の評価には長期の観察が必要である。

A. 研究目的

ポリープ状脈絡膜血管症 (PCV) に対する光線力学療法 (PDT) の効果を明らかにする。

B. 対象および方法

対象は平成 16 年 6 月から 9 月までにフルオレセイン蛍光造影 (FA) で中心窩に CNV の所見があり、インドシアニンググリーン蛍光造影 (IA) で PCV と診断し、PDT を施行し、12 か月間経過観察ができた 37 例 37 眼であった。性別は男性 21 例、女性 16 例であった。年齢は 52 歳～89 歳、平均年齢は 67.5 歳であった。

検討項目は、PDT 施行回数、視力の推移、

IA でのポリープ状病巣と異常血管網の変化であった。視力の評価は log MAR 視力で 0.2 以上の変化で改善、悪化とした。ポリープ状病巣は全部消失、減少、不変、に分類し、異常血管網はすべて消失、長径の減少、不変に分類し評価した。

C. 研究結果

PDT 施行回数は、1 回が 14 眼、2 回が 11 眼、3 回が 9 眼、4 回が 3 眼で、平均施行回数は 2.0 回であった。GLD は、2250 μm –7000 μm (平均 4134 μm) であった。12 か月後の視力は、改善 12 眼 (33%)、不変 16 眼 (43%)、悪化 9 眼 (24%) であった。12 か月後の IA で、ポリープ状病巣は全部消失 31 眼

(84%) 半数以下に減少 3 眼 (8%)、出血のため判定不能 3 眼 (8%)、一方異常血管網は消失なく、長径が半分以下に減少 6 眼 (16%)、不変 28 眼 (76%)、出血のため判定不能 3 眼 (8%) であった。9 か月後に 2 眼、12 か月後に 1 眼で、残存した異常血管網の辺縁にポリープ状病巣の再発をみとめた (図 1-3)。

D. 考察

今回我々の結果では、PDT後の視力改善は 37 眼中 28 眼 (33%) であった。過去の報告では、PDT後の視力改善・不変は、Chan WM (2003 年) は 22 眼中 21 眼 (95%)、Lee SC (2004 年) は 9 眼中 8 眼 (89%)、Hessian N (2005 年) は、9 眼中 9 眼 (100%) であった。これらを合わせて考えると、PDTはPCVを有する症例の12か月間の視力の改善・維持に有効であると考えた。

今回の結果では、ポリープ状病巣の消失あるいは減少が 97%に見られた。これは、ポリープ状病巣を形成する血管は異常血管網の末端にあり、比較的細く PDT で閉塞しやすいためと考えた。一方、異常血管網は不変が 85%であった。これは、異常血管網はポリープ状病巣より中枢側にあり、また比較的太い血管も多いため、PDT で閉塞しにくく、残った異常血管網がポリープの再発につながるのではないかと考えた。

E. 結論

PCVに対するPDTは12か月後の視力の改善、不変に有効であることがわかった。PDT後、異常血管網は残存するので、ポリープ状病巣が再発する可能性があるので長期に

経過観察をする必要があると考えた。

F. 健康危険情報

なし

G. 研究発表

1. 論文発表

なし

2. 学会発表

1. 赤座英里子 他:ポリープ状脈絡膜血管症にみられる拍動.第109回日本眼科学会総会 京都府, 2005
2. 赤座英里子 他: ポリープ状脈絡膜血管症に対する光線力学療法の効果.第43回網膜硝子体学会, 2005

H. 知的財産権の出願・登録状況

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

I. 参考文献

1. Yannuzzi LA, et al: Idiopathic polypoidal choroidal vasculopathy(IPCV). Retina.10: 1-8, 1990.
2. Yannuzzi LA, et al:The Expanding Clinical Spectrum of Idiopathic Polypoidal Choroidal Vasculopathy.ArchOphthalmol 115,478-485, 1997.
3. Lee SC, et al: Photodynamic therapy with verteporfin for polypoidal

choroidal vasculopathy of the macula.

Ophthalmologica 218:193-201, 2004.

4. Chan WM, et al: Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmol 111: 1576-1584, 2004.
5. Rosenblatt BJ et al: Photodynamic therapy with verteporfin for peripapillary choroidal neovascularization. Retina. 25: 33-37, 2005.
6. Hussain N et al: Role of photodynamic therapy in polypoidal choroidal vasculopathy. Indian J Ophthalmol 53: 101-104, 2005.




表 1 視力の推移




図 1 再発例 PDT 施行前




図 2 再発例 PDT 施行後 3 か月




図 3 再発例 PDT 施行後 9 か月